Anti-MSLN CARs facilitated paclitaxel delivery and cytotoxic granules to tumor cells, while anti-PD-L1 CARs efficiently reversed the immunosuppressive effect of the tumor microenvironment. This evidence concerns the gene MSLN and neoplasm.